Navigation Links
FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir
Date:10/12/2007

Data Show Lower Dose Associated with Fewer Adverse Events in Healthy

Volunteers

RESEARCH TRIANGLE PARK, N.C., Oct. 12 /PRNewswire-FirstCall/ -- GlaxoSmithKline's (NYSE: GSK) HIV protease inhibitor LEXIVA(R) (fosamprenavir calcium) may now be administered with 100mg of ritonavir, an agent that increases, or boosts, the level of protease inhibitors in the bloodstream.

The U.S. Food and Drug Administration approved once-daily LEXIVA 1400 mg with 100mg of ritonavir in adult patients who had not previously taken a protease inhibitor (PI). The approval was based on pharmacokinetic data demonstrating comparable blood plasma levels in healthy volunteers when LEXIVA was administered with the lower 100mg dose of ritonavir and the previously approved 200mg dose of ritonavir. This information has been added to the LEXIVA product label.

LEXIVA is indicated in combination with other antiretrovirals for the treatment of HIV infections. Ritonavir works with LEXIVA and other protease inhibitors to boost the medication level in the bloodstream making the protease inhibitor more effective in suppressing HIV. HIV medicines do not cure HIV infections/AIDS or prevent passing HIV to others.

"GlaxoSmithKline remains committed to improving patient care by making dosing options more convenient," said Mark Shaefer, Pharm. D., Director, Clinical Development at GlaxoSmithKline. "We understand that reducing the number of pills taken daily is an important consideration for patients starting HIV treatment."

The data supporting this label change were published in the February 2007 issue of Antimicrobial Agents and Chemotherapy.

LEXIVA Indication Statement and Background

LEXI
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Lowering the fear factor for entrepreneurs, intra-preneurs
9. Immune boosting beverage relying on Milwaukee firms packaging technology
10. GE Healthcare develops digital medication system

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...rio, Nov. 6 Helix BioPha...oday announced that John Docherty, president and c...urhan Ford,s 6th annual Investor Summit on Novembe...York City. Mr. Docherty will provide an overview ...ams L-DOS47 and Topical Interferon Alpha-2b. The ...
(Date:11/6/2009)...Y, Calif., Nov. 6 Calbiotech, Inc....Business Innovative Research (SBIR) Phase I contra...command. Under terms of the agreement, Calbiotech ...the diagnosis of Dengue virus. ,, Dengue vir... major threat to military forces deployed to tropi...
(Date:11/5/2009)...N -- Gone hybrid . . . , Fuel economy ratings ...sted at the www.fueleconomy.gov web site, which ...ins for the U.S. Department of Energy and the U.S....10 vehicles on the best fuel economy list are hybr...; 48 highway). "This list proves that hybrids have...
(Date:11/5/2009)...ov. 5 Imagenetix, Inc. (...lliam Spencer, President and CEO of Imagenetix, wi...nual LD MICRO Conference on Thursday, December 3rd...s. ,, About LD MICRO ,, LD MICRO is a by-inv...ng undervalued companies in the micro-cap space. S...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2
...ociates, Inc.,administrator for the HealthShares(T...the HealthShares(TM) Exchange-Traded Funds, today ... on Tuesday February 26, 2008, KV,Pharmaceutical C...ls, Inc.,(NYSE: BDY ) in the HealthShares(TM) Der...quired by Nycomed US Inc., a subsidiary of Nycomed...
...ration,(Nasdaq: BPUR ) today announced its financ...uary 31, 2008. For the quarter, the company report... share, compared with a net loss,of $6.9 million, ...eriod in,2007. Class A common shares outstanding o...,543,025, respectively., Revenues, Total revenue...
...ntered into an Agreement Under, Which Genmab Will ...ted in Brooklyn Park, Minnesot...ifornia, February 21, Genmab A/S (OMX: GEN) and PD... that they have entered into an agreement,under wh...ing facility,located in Brooklyn Park, Minnesota, ...
Other Biology Technology:Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5
(Date:11/4/2009).... Louis, MO, November 4, 2009 Childhood obesity i...ns. With more than one fourth of advertising on da...nd beverages and continuing questions about the ro...ember/December issue of the Journal of Nutrition ...ing aimed at children might be a large contributor...
(Date:11/4/2009)..., PORTOLA VALLEY, Calif., Oct. 19 ...olecular sensing and imaging devices which shed li...that it has signed exclusive distribution deals fo...nsors. The markets covered include Australia, New...enelux), Suriname, Italy, France, Spain, Portugal,...
(Date:11/4/2009)..., RIDGE, N.Y., Oct. 21 What,s the ...eventing accidental death resulting from prescript...s with good intentions, however, may be unaware th...ting their teens from the ticking timebomb of pres...leader in premium-quality medical supplies, has fo...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Spectros Signs New International Distribution Deals 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3AMA Medicare Campaign Kicks Off With New TV Ads 59585 1AMA Medicare Campaign Kicks Off With New TV Ads 59585 2AMA Medicare Campaign Kicks Off With New TV Ads 59585 3Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 1Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 2ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 1ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 2
...of Standards and Technology (NIST) last week issue... and growing field of tissue engineering for medic...al tissue scaffold material that have been measure...es of porosity. , Three-dimensional tissue scaffo...adable materials that are meant to be implanted in...
...nt pieces of the climate change puzzle together is...is a key piece of this puzzle, but the size and sh...opardises the reliability of all current predictio...ct has been launched at the University of Leeds to...te. , Aerosols are small particles suspended in...
...f melanin -- the color pigment in skin and hair --...sed susceptibility to nicotine dependence and toba...rs, according to scientists., "We have found that...to the number of cigarettes smoked daily, levels o... African Americans," said Gary King, professor of ...
Other Biology News:NIST issues first reference material for tissue engineering 2Aerosol: A key piece of the climate change puzzle 2Skin color clue to nicotine dependence 2
Anti-Mouse VEGF-C Antibody, Unconjugated from Raybiotech, Inc.
Annexin V Binding Buffer from BD Biosciences Pharmingen
Mouse Anti-Cytokeratin 8 + 18 + 19 Monoclonal Antibody, Unconjugated, Clone 2A4 from Abcam
Tube-O-DIALYZER Floats, Floats, Small from CHEMICON
Biology Products: